- Home
- URGN vs IRMD Comparison
URGN vs IRMD Comparison
Compare URGN & IRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- IRMD
- Stock Information
- Founded
- URGN 2004
- IRMD 1992
- Country
- URGN United States
- IRMD United States
- Employees
- URGN N/A
- IRMD N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- IRMD Medical/Dental Instruments
- Sector
- URGN Health Care
- IRMD Health Care
- Exchange
- URGN Nasdaq
- IRMD Nasdaq
- Market Cap
- URGN 547.1M
- IRMD 618.5M
- IPO Year
- URGN 2017
- IRMD 2014
- Fundamental
- Price
- URGN $11.19
- IRMD $51.99
- Analyst Decision
- URGN Strong Buy
- IRMD Strong Buy
- Analyst Count
- URGN 5
- IRMD 1
- Target Price
- URGN $44.50
- IRMD $60.00
- AVG Volume (30 Days)
- URGN 456.4K
- IRMD 36.4K
- Earning Date
- URGN 11-06-2024
- IRMD 10-31-2024
- Dividend Yield
- URGN N/A
- IRMD 1.15%
- EPS Growth
- URGN N/A
- IRMD 13.16
- EPS
- URGN N/A
- IRMD 1.46
- Revenue
- URGN $89,363,000.00
- IRMD $71,305,130.00
- Revenue This Year
- URGN $14.43
- IRMD $13.29
- Revenue Next Year
- URGN $44.44
- IRMD $10.76
- P/E Ratio
- URGN N/A
- IRMD $35.61
- Revenue Growth
- URGN 15.64
- IRMD 13.23
- 52 Week Low
- URGN $10.60
- IRMD $40.05
- 52 Week High
- URGN $20.70
- IRMD $57.95
- Technical
- Relative Strength Index (RSI)
- URGN 35.94
- IRMD 48.18
- Support Level
- URGN $11.93
- IRMD $55.40
- Resistance Level
- URGN $12.78
- IRMD $57.95
- Average True Range (ATR)
- URGN 0.71
- IRMD 2.33
- MACD
- URGN -0.05
- IRMD -0.04
- Stochastic Oscillator
- URGN 1.36
- IRMD 46.26
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About IRMD iRadimed Corporation
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.